Nebu-Flow secures £4.7m to accelerate next generation respiratory pharmaceuticals

Nebu-Flow has secured an additional £4.7 million of investment to accelerate the next generation of inhaled drugs for patients with respiratory disorders, which are the main cause of death and disability worldwide.

For full details please click here.